‘Ozempic penis’: what the evidence actually says about size and sexual function

What the source reports

‘Ozempic penis’ is an informal expression circulating on social media and in news coverage. It is not a recognised medical condition, an indication for treatment, or a term used in the current US Ozempic prescribing information.

Posts using the phrase often combine two separate ideas: that weight loss has exposed more of the penile shaft, and that sexual function has changed. Neither observation demonstrates that semaglutide caused penile tissue to grow.

Ozempic and Wegovy contain semaglutide but are different products with different labelled uses. The viral phrase also risks attributing every change during treatment directly to a medicine when weight loss, diabetes, cardiovascular health, hormones, other medicines and psychological factors can all affect sexual health.

No evidence that semaglutide increases penile tissue size

We found no clinical trial showing that semaglutide, tirzepatide or another GLP-1 medicine increases adult penile tissue length or girth. Penile enlargement is not listed as an adverse reaction in the current US Ozempic label.

That absence does not prove that no individual will notice a change in appearance. It means the specific claim that the medicine makes the penis grow is not supported by clinical evidence or a demonstrated biological mechanism.

The distinction between anatomical length and visible length matters. Researchers can measure from the pubic bone to the tip, which compresses the fat pad, or from the surface of the suprapubic skin to the tip. Changes in tissue around the base can affect the second measurement without changing the penis itself.

Why weight loss may change visible length

In a study of 778 men, average erect length measured from the pubic bone to the tip was 14.34 cm, compared with 12.53 cm from the suprapubic skin to the tip. Body mass index had a weak negative relationship with the skin-to-tip measurement but not the bone-to-tip measurement. This supports the principle that fat around the base can conceal part of the shaft; it does not measure change caused by a GLP-1 medicine.

A small prospective study of 46 men used cryolipolysis—not weight-loss medicine—to reduce suprapubic fat. Mean apparent stretched length rose from 12.1 cm to 12.88 cm while the suprapubic skin fold became thinner. The study had no untreated control group and cannot tell us what ordinary weight loss or semaglutide would do.

Claims that weight loss will routinely reveal 1–2 inches, or 2.5–5 cm, are therefore too certain. The amount, if any, will vary with anatomy, where fat is lost, skin laxity and measurement technique. We did not find good evidence supporting that range as a general expectation for GLP-1 users.

Buried penis is a real condition—but not every visual change is one

Adult-acquired buried penis is a recognised condition in which abdominal or suprapubic skin or fat conceals the penis. Severe cases can involve difficulty urinating, recurrent skin infections, problems with hygiene and sexual dysfunction. Obesity is a common cause, but scarring, lymphoedema, inflammatory skin disease and previous surgery can also contribute.

Weight loss may improve visibility for some people, but it is not a guaranteed solution for established buried penis. Loose skin and other tissue changes can remain after major weight loss, and some people need assessment by a urologist or reconstructive specialist.

A 2026 survey following bariatric surgery included only 11 men classified as having adult-acquired buried penis. It found trends towards better anatomical, urinary and sexual function, but most comparisons were not statistically significant. That small retrospective result supports caution rather than a universal centimetre estimate.

Erectile function: the evidence is conflicting

It is reasonable to ask whether improvements in weight, glucose control and cardiovascular risk might accompany better erections. Studies after bariatric surgery have reported improved erectile-function scores, but that does not establish the effect of a particular GLP-1 medicine.

Research specifically involving GLP-1 medicines does not yet give a simple answer. A 2025 systematic review of diabetes treatments suggested GLP-1 receptor agonists performed better than metformin on erectile-function measures in the small number of available studies. A 2026 review covering eight GLP-1 studies and 375 participants also reported generally positive metabolic, hormonal and erectile outcomes, while noting a limited evidence base.

In the opposite direction, a matched US health-record study of 3,094 non-diabetic men aged 18–50 prescribed semaglutide for obesity found a new erectile-dysfunction diagnosis or phosphodiesterase-5 prescription in 1.47%, compared with 0.32% among matched men without a semaglutide prescription. This observational result cannot prove causation and may be affected by healthcare use, prescribing patterns or unmeasured differences, but it should not be ignored.

Taken together, the evidence does not justify promising firmer erections or describing erectile change as a standard effect of semaglutide. Nor does it establish that semaglutide commonly causes erectile dysfunction. Better controlled, medicine-specific studies are needed.

What remains uncertain

No well-designed study has measured anatomical and visible penile length before and after GLP-1 treatment, so the frequency and average size of any perceived change are unknown. Social-media reports cannot supply a denominator or separate medicine effects from weight loss.

Studies of sexual function use different medicines, populations and outcome measures, and several are small or observational. Future prospective trials would need to record baseline erectile function, weight change, diabetes control, hormones, cardiovascular health and other medicines to identify what—if anything—the GLP-1 treatment itself changes.

When an individual change deserves medical attention

A change noticed during treatment is still real to the person experiencing it, even when the cause is uncertain. Persistent difficulty getting or maintaining an erection, penile pain, new curvature, loss of sensation, urinary problems, skin inflammation, or difficulty exposing the penis should be discussed with a qualified healthcare professional.

Erectile dysfunction can sometimes be an early sign of cardiovascular or metabolic disease. A clinician can also review other medicines, hormone symptoms, mental health and relationship factors rather than assuming a GLP-1 medicine is either the cause or the cure.

Do not stop or change a prescribed medicine because of a social-media story. Speak with the prescriber, particularly if a symptom began after starting treatment or changing dose.

Bottom line

There is no evidence that semaglutide makes penile tissue grow. Loss of fat around the lower abdomen and pubic area can plausibly expose more of an existing shaft, changing visible or skin-to-tip length without changing bone-to-tip anatomical length.

We cannot say how common this perception is among GLP-1 users, and the widely repeated 1–2 inch figure is not supported as a general expectation. Evidence about erectile function during GLP-1 treatment is limited and conflicting.

‘Ozempic penis’ is therefore best understood as a viral label attached to several possible body and sexual-health changes—not a known drug effect or a medical diagnosis.